115 related articles for article (PubMed ID: 15902765)
1. Third Tysabri adverse case hits drug class.
Sheridan C
Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765
[No Abstract] [Full Text] [Related]
2. Tysabri raises alarm bells on drug class.
Sheridan C
Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649
[No Abstract] [Full Text] [Related]
3. Tysabri withdrawal calls entire class into question.
Singer E
Nat Med; 2005 Apr; 11(4):359. PubMed ID: 15812500
[No Abstract] [Full Text] [Related]
4. Natalizumab: bound to rebound?
Schiess N; Calabresi PA
Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
[No Abstract] [Full Text] [Related]
5. Tysabri risk causing headache for companies.
Sheridan C
Nat Rev Drug Discov; 2005 Sep; 4(9):703-4. PubMed ID: 16178114
[No Abstract] [Full Text] [Related]
6. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
7. Reply to "'Thinking without thinking' about natalizumab and PML".
Houff S; Berger JR
J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
[No Abstract] [Full Text] [Related]
8. The trials and tribulations of Tysabri.
Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299
[No Abstract] [Full Text] [Related]
9. PML risk and natalizumab: more questions than answers.
Ransohoff RM
Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
[No Abstract] [Full Text] [Related]
10. MS drug withdrawn from market.
FDA Consum; 2005; 39(3):3. PubMed ID: 16127808
[No Abstract] [Full Text] [Related]
11. Natalizumab (Tysabri) returns.
Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
[No Abstract] [Full Text] [Related]
12. [Natalizumab in multiple sclerosis: unclear patient benefits].
Schipper JP
Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
[TBL] [Abstract][Full Text] [Related]
13. Lessons for clinical trials from natalizumab in multiple sclerosis.
Chaudhuri A
BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
[TBL] [Abstract][Full Text] [Related]
14. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
Vennegoor A; Wattjes MP; van Munster ET; Kriekaart RL; van Oosten BW; Barkhof F; Killestein J; Polman CH
Neurology; 2011 Feb; 76(6):574-6. PubMed ID: 21300973
[No Abstract] [Full Text] [Related]
15. Balancing risk and reward: the question of natalizumab.
Hauser SL; Johnston SC
Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
[No Abstract] [Full Text] [Related]
16. [Treatment of multiple sclerosis].
Holmøy T; Harbo HF; Celius EG
Tidsskr Nor Laegeforen; 2010 May; 130(9):923; author reply 923. PubMed ID: 20453948
[No Abstract] [Full Text] [Related]
17. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
Berger T; Deisenhammer F
N Engl J Med; 2005 Oct; 353(16):1744-6; author reply 1744-6. PubMed ID: 16236749
[No Abstract] [Full Text] [Related]
18. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab: a double-edged sword?
DeAngelis LM
Ann Neurol; 2009 Sep; 66(3):262-3. PubMed ID: 19798644
[No Abstract] [Full Text] [Related]
20. MS drug back on market under restricted program.
FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
